Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
The company declared rather influential deterioration in their top-line, amid the fiscal second quarter of 2022
company delivered second quarter of 2022 operating deficit of $-280.766 millions
Published Nov 16 2022
CSIMarket Team / CSIMarket.com
Revenues decreased extensively by -10.395 % to $12.53 millions from $13.99 millions in the similar reporting period a year prior and sequentially Revenue doubled by 190.183 % from $4.32 millions.
For the fiscal span ending September 30 2022 Roivant Sciences Ltd realized net loss of $-315.921 million, bigger than $-225.640 million a year ago.
Roivant Sciences Ltd is expected to report next financial earnings on June 27, 2023.
Other ROIV's news
IMVT-1402: Transforming the Landscape of Autoimmune Disease Treatment with Best-in-Class Potential
Roivant Sciences Ltd: A Remarkable 400% Revenue Growth in Q1 2023 Amidst Mounting Deficit
The Top-line took a nose-dive at ROIV during the third quarter of 2022 earnings season
Severe hit for the company in the financial first quarter of 2022
Other ROIV's news
IMVT-1402: Transforming the Landscape of Autoimmune Disease Treatment with Best-in-Class Potential
Roivant Sciences Ltd: A Remarkable 400% Revenue Growth in Q1 2023 Amidst Mounting Deficit
The Top-line took a nose-dive at ROIV during the third quarter of 2022 earnings season
Severe hit for the company in the financial first quarter of 2022